Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | NBTXR3 with radiotherapy and anti-PD-1 therapy in anti-PD-1-resistant melanoma

Jason Chan, MD, University of California, San Francisco, CA, discusses dose expansion results from the Phase I (NCT03589339) study evaluating a single intratumoral injection of NBTXR3, a hafnium oxide nanoparticle radioenhancer, followed by stereotactic body radiation therapy and anti-PD-1 therapy in patients with anti-PD-1-resistant advanced melanoma. The approach was feasible and well tolerated, with few high-grade treatment-related adverse events. Encouraging response and disease control rates were observed, including responses in unirradiated lesions suggesting a systemic immune effect, supporting further evaluation in randomized trials. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So speaking to safety first, we found that the safety profile was overall acceptable and the treatment was well tolerated. So there were two grade three toxicities at the time of the actual intervention. And both of these were transient grade 3 toxicities that did not impact radiation or the subsequent resuming of immunotherapy. So one was transient hypotension and then the other one was pleuritic pain after injection to that site...

So speaking to safety first, we found that the safety profile was overall acceptable and the treatment was well tolerated. So there were two grade three toxicities at the time of the actual intervention. And both of these were transient grade 3 toxicities that did not impact radiation or the subsequent resuming of immunotherapy. So one was transient hypotension and then the other one was pleuritic pain after injection to that site. But these had resolved shortly after the injection and did not have anything to do with the actual product itself and then later side effects there was one case of grade 3 skin fibrosis at the site of injection most of the other side effects were all lower grade and the majority of them were attributed to radiation that had resolved on their own and then as far as efficacy goes the overall response rate we saw was 42 percent and we wanted to see if we had different response rates at the site that was injected and radiated and also sites that were not intervened on and so we did see responses for both so for the sites that were injected and radiated, the response rate was about 45%. And then for the non-injected lesions, so-called abscopal responses, we saw about a 30% response rate. So for the non-injected, non-irradiated lesions, very small number. We only had 10 to look at, and then there were three responses so 30% so very small numbers early days but there is an efficacy signal

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.